Aeglea BioTherapeutics, Inc. (AGLE): Price and Financial Metrics
GET POWR RATINGS... FREE!
AGLE POWR Grades
- Sentiment is the dimension where AGLE ranks best; there it ranks ahead of 96.75% of US stocks.
- AGLE's strongest trending metric is Momentum; it's been moving up over the last 134 days.
- AGLE ranks lowest in Stability; there it ranks in the 7th percentile.
AGLE Stock Summary
- As for revenue growth, note that AGLE's revenue has grown -87.57% over the past 12 months; that beats the revenue growth of merely 1.54% of US companies in our set.
- The volatility of AEGLEA BIOTHERAPEUTICS INC's share price is greater than that of 93.36% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AGLE comes in at -197.76% -- higher than that of only 3.2% of stocks in our set.
- Stocks that are quantitatively similar to AGLE, based on their financial statements, market capitalization, and price volatility, are VSTM, TMBR, UTSI, CRBU, and PRTC.
- Visit AGLE's SEC page to see the company's official filings. To visit the company's web site, go to www.aegleabio.com.
AGLE Valuation Summary
- In comparison to the median Healthcare stock, AGLE's price/earnings ratio is 101.29% lower, now standing at -0.3.
- Over the past 85 months, AGLE's price/sales ratio has gone down 9.1.
Below are key valuation metrics over time for AGLE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AGLE | 2023-03-24 | 9.3 | 0.4 | -0.3 | 0.1 |
| AGLE | 2023-03-23 | 9.1 | 0.4 | -0.3 | 0.1 |
| AGLE | 2023-03-22 | 9.3 | 0.4 | -0.3 | 0.1 |
| AGLE | 2023-03-21 | 9.1 | 0.4 | -0.3 | 0.1 |
| AGLE | 2023-03-20 | 8.4 | 0.4 | -0.2 | 0.1 |
| AGLE | 2023-03-17 | 8.8 | 0.4 | -0.2 | 0.1 |
AGLE Growth Metrics
- Its 5 year cash and equivalents growth rate is now at -16.11%.
- Its 4 year price growth rate is now at 26.12%.
- The year over year net cashflow from operations growth rate now stands at 17.88%.
The table below shows AGLE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 5.805 | -81.272 | -85.439 |
| 2022-06-30 | 7.03 | -83.204 | -87.512 |
| 2022-03-31 | 20.101 | -60.449 | -72.019 |
| 2021-12-31 | 18.739 | -53.716 | -65.801 |
| 2021-09-30 | 15.095 | -51.58 | -68.069 |
| 2021-06-30 | 13.696 | -52.116 | -65.795 |
AGLE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AGLE has a Quality Grade of D, ranking ahead of 14.56% of graded US stocks.
- AGLE's asset turnover comes in at 0.087 -- ranking 276th of 681 Pharmaceutical Products stocks.
- REGN, MNKD, and JAZZ are the stocks whose asset turnover ratios are most correlated with AGLE.
The table below shows AGLE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.087 | 1 | -0.879 |
| 2021-03-31 | 0.000 | NA | -1.076 |
| 2020-12-31 | 0.000 | NA | -1.144 |
| 2020-09-30 | 0.000 | NA | -1.166 |
| 2020-06-30 | 0.000 | NA | -1.351 |
| 2020-03-31 | 0.000 | NA | -1.363 |
AGLE Price Target
For more insight on analysts targets of AGLE, see our AGLE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.50 | Average Broker Recommendation | 1.56 (Moderate Buy) |
AGLE Stock Price Chart Interactive Chart >
AGLE Price/Volume Stats
| Current price | $0.29 | 52-week high | $3.17 |
| Prev. close | $0.29 | 52-week low | $0.29 |
| Day low | $0.29 | Volume | 301,800 |
| Day high | $0.30 | Avg. volume | 308,047 |
| 50-day MA | $0.42 | Dividend yield | N/A |
| 200-day MA | $0.55 | Market Cap | 18.96M |
Aeglea BioTherapeutics, Inc. (AGLE) Company Bio
Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. The company was founded in 2013 and is based in Austin, Texas.
Latest AGLE News From Around the Web
Below are the latest news stories about AEGLEA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate AGLE as an investment opportunity.
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue EstimatesAeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program UpdatesAeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates. |
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) insiders placed bullish bets worth US$695k in the last 12 monthsGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off Friday with an overview of the biggest pre-market stock movers traders will want to keep an eye on today! |
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational EfficiencyAeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure. These changes are in addition to the restructuring process that was initiated in August 2022 and are intended to further streamline the organization, create operational efficiencies to support near- and long-term objectives and maximize the value of the |
AGLE Price Returns
| 1-mo | -26.60% |
| 3-mo | -35.54% |
| 6-mo | -44.87% |
| 1-year | -87.39% |
| 3-year | -93.78% |
| 5-year | -97.08% |
| YTD | -35.54% |
| 2022 | -90.53% |
| 2021 | -39.64% |
| 2020 | 3.01% |
| 2019 | 2.00% |
| 2018 | 38.45% |
Loading social stream, please wait...